Introduction 1
Neuroendocrine neoplasms (NENs) represent a heterogeneous group of neoplasms with a 2 moderate but steadily increasing annual age-adjusted incidence of approximately 7/100,000 3 for the USA in 2012 (1). Most NENs grow rather slowly and may develop into a more 4 aggressive phenotype while being undetected. Tumor growth often goes unnoticed and 5 diagnosis may be delayed for many years after the onset of disease, until metastatic spread. 6
At this point, local surgery as the only curative therapy is not feasible anymore (2). Among 7 treatment options for advanced tumors are targeted therapies with mTOR inhibitors 8 (everolimus), tyrosine kinase inhibitors (sunitinib) and somatostatin analogs (SSAs) as NENs 9 frequently express somatostatin receptors (SSTRs) (3). Autoradiographic receptor detection, 10 in-situ hybridization and immunohistochemistry demonstrated high SSTR2 overexpression in 11 tumors with little background in other tissues (4-6). SSAs such as octreotide and lanreotide 12 are used as antisecretory and antiproliferative medication. Apart from direct pharmacological 13 intervention, SSTR overexpression in NENs has also been utilized for targeted molecular 14 imaging and peptide receptor radiotherapy (PRRT) (7-10). 15
Although SSTR-based imaging and therapy is an important option in the management of 16
NENs, it is estimated that up to 30 % of patients do not fully benefit from these approaches. 17
Whereas some tumors lack SSTR expression or downregulate expression upon treatment, 18 others exhibit an inhomogeneous receptor distribution resulting in a residual tumor mass 19 after treatment and subsequent resistance to SSAs (11, 12) . Other possible resistance 20 mechanisms include: receptor desensitization, downregulation or loss-of-function as well as 21 altered signaling pathways (12, 13) . Most patients develop SSA resistance within weeks to 22 months of treatment, with recurrent symptoms and tumor growth (14) . As a consequence, to 23 extend the repertoire of available ligands for imaging and therapy, alternative peptide GPCRs 24 are investigated. 25
To identify alternative target receptors at the cell surface of NENs, this study used high-26
throughput screening technology to detect G protein-coupled receptor (GPCR) activation in 27
Material and Methods 1
Reagents 2
If not indicated otherwise, chemicals were obtained from Sigma Aldrich (St. Louis, MO, 3 USA). G αq inhibitor UBO-QIC was purchased from the Institute of Pharmaceutical Biology, 4
University of Bonn (Germany), AKT-Inhibitor AZD-5363, #A9601, from LKT laboratories (St 5
Paul, MN, USA), ERK-Inhibitor SCH772984, #B1682-5, from BioVision (Milpitas, CA, USA), 6 β-arrestin inhibitor barbadin, #Axon2774, from Axon Medchem (Groningen, Netherlands). 7
Compound library 8
The compound library used for screening consisted of the following components: compounds 9 1-866 were from the G-Protein Coupled Receptor (GPCR) Peptide Ligand Library (Phoenix 10 Pharmaceuticals, Burlingame, CA, USA), compounds 867-956 from the Orphan Peptide 11
Ligand Library (Qventas Labs, Branford, CT, USA), and compounds 957-998 from various 12 sources. All compounds in the library are listed in Supplementary Table 1 . 13
Cell culture 14
If not indicated otherwise, cell culture reagents were obtained from Biochrom AG (Berlin, 15 Germany). The human NEN cell lines BON and QGP-1 (pancreatic), LCC-18 (colonic), H727 16 and UMC-11 (pulmonary) and all other cell lines were cultured in RPMI 1640 supplemented 17 with 10 % fetal calf serum in a humidified atmosphere at 37 °C and 5 % CO 2 . BON cells were 18 a kind gift of Courtney Townsend (University of Texas, Galveston, USA). LCC-18 were kindly 19 donated by Kjell Öberg (University of Uppsala, Sweden) and KRJ-1 by Dr. Irvin Modlin (Yale 20 University, USA). QGP-1 were obtained from the Japanese Collection of Research 21
Bioresources. All other cell lines were obtained from Cell Line Services (Heidelberg, 22 Germany), DSMZ (Braunschweig, Germany) or ATCC (Manassas, VA, USA). Cells were 23 cultured for no more than 20 passages. Mycoplasma testing was done at least every six 24 months. Cell lines were authenticated by STR analysis at DSMZ (Braunschweig, Germany). 25
Due to the lack of reference profiles for BON and LCC-18, their respective STR profile was 26 characterized as unique and not contaminated with any known cell line. The results of the 27 STR profiling for BON and LCC-18 are provided in the table below. 28 This study was carried out in accordance with the recommendations and protocol approval 4 by the local ethics committee at Charité -Universitätsmedizin Berlin with written informed 5 consent from all subjects, in accordance with the Declaration of Helsinki. Samples were 6 flash-frozen after surgical resection and stored at -80 °C until further use. 7 8
Reverse transcription quantitative real-time PCR (RT-qPCR) 9
RNA isolation, reverse transcription and quantitative real-time PCR were performed as 10 previously described (15). Oligonucleotide primer sequences are indicated in Table 2 . Plotted 11 values were corrected for different primer efficiencies and normalized on the geometric mean 12 of UBC, ALG9 and HPRT1 using the ∆∆Ct method (16) . Reference genes were validated 13 and chosen using the geNorm algorithm (17) by qbase+ software (Biogazelle, Ghent, 14 Belgium). 15 16 
Radioactive studies 1
Peptide iodination was performed as previously described (18). Briefly, 10 nmol 2 angiotensin II (Sigma, Deisenhofen, Germany) were iodinated with 1 mCi carrier-free Na 125 I 3 (NEZ033L010MC, Perkin Elmer, Waltham, MA, USA) and purified by HPLC (Analytic HPLC 4 1200 Series, Agilent, Santa Clara, CA, USA; see Figure S1 in supplementary material). The 5 method for the competitive binding assay was described in detail before (15). For saturation 6 experiments, binding buffer was prepared with varying concentrations of 125 I-angiotensin II, 7 either with (non-specific binding) or without 1 µM of additional unlabeled peptide (total 8 binding). Non-specific binding was subtracted from total binding to obtain specific binding. 9
Obtained cpm values were plotted with GraphPad Prism 5.04 and fitted using nonlinear 10 regression (one site-fit K i for competition data, one site -total and non-specific/one site -11 specific binding for saturation data). 12 13
In vitro receptor autoradiography 14
Flash-frozen human and mouse tissue samples were cut into 10-20 µm thick sections using 15 a cryomicrotome, mounted on glass slides, dried and stored at -80 °C. On the day of the 16 experiment, slides were thawed, tissues encircled with a Dako Pen and incubated with 200 µl 17 binding buffer (50 mM Hepes pH 7.4, 5 mM MgCl 2 , 1 mM CaCl 2 , 0.5 % BSA, cOmplete 18 protease inhibitors) containing 0.5 nM radiolabeled 125 I-angiotensin II (total binding). Non-19 specific binding was assessed on consecutive sections by additional incubation with 1 µM of 20 unlabeled peptide. After 1-2 h at 37 °C, slides were transferred to glass cuvettes, washed 21 three times for 1 min with washing buffer (50 mM Tris-HCl, pH 7.4, 125 mM NaCl, 0.05 % 22 BSA), shortly dipped into water and quickly dried under a stream of air. Slides were exposed 23 to Amersham Hyperfilm MP (GE Healthcare, Buckinghamshire, UK) for 1-2 weeks at room 24 temperature. Developed films were scanned and analyzed with ImageJ. In addition to 25 densitometric quantification, tissue sections were carefully wiped off the slides using filter 26 paper and measured in a gamma counter. Additional tissue sections were stained with 27 hematoxylin and eosin for comparison with the corresponding autoradiograms. 28
Calcium mobilization 1
Experiments in 96-well format were performed as previously described (18). For 384-well 2 experiments, 15,000 to 20,000 cells per well were seeded after plate coating and for any 3 incubation and washing steps 20 µl total volume were used. For experiments using 4 antagonists, these were diluted in washing buffer/0.5% BSA, added to the cells after the 5 second washing step in double concentration and incubated for 15 min before measurement. 6 7 DMR assay 8 384-well or 96-well BIND CA1 biosensor plates (SRU Biosystems, Woburn, MA, USA) were 9 seeded with 15,000/50,000 cells per well. The next day, cells were incubated with 25/100 µl 10 serum-free medium for 10 min at room temperature. A buffer baseline was obtained on the 11 dynamic mass redistribution (DMR) reader (BIND reader, SRU Biosystems) for 12 approximately 5 min before compounds were added by a 96-well pipette (Liquidator 96, 13
Mettler Toldedo, Gießen, Germany) within 30-60 sec. DMR data were acquired for 45 14 minutes and exported using EMS Export Wizard (SRU Biosystems). A compound was 15 regarded a hit if its trace contained at least three data points with a read higher than the 16 mean ± 3 standard deviations of the negative control (buffer only). For EC 50 calculations, 17 data points with the highest shift between buffer control and compound dilution were used 18 and plotted with GraphPad Prism 5.04. 19 20 Impedance assay 21 50,000 BON cells were seeded per well into 96-well impedance sensor plates (Bionas, 22
Rostock, Germany). The next day, cells were incubated with 100 µl serum-free medium for 23 10 min at room temperature. A buffer baseline was obtained on the impedance reader 24 (Adcon reader, Bionas) for approximately 5 min before compound dilutions (100 µl) were 25 added by a 12-channel pipette within 30-60 sec. Impedance data were acquired for 45 26 minutes and data points with the highest shift between buffer control and compound dilution 27 were used to calculate EC 50 values using GraphPad Prism 5.04. 28
Chromogranin A ELISA 1 30,000 BON cells per well were seeded in 96-well plates and grown overnight. The next day, 2 ligands were diluted in serum-free medium/0.5 % BSA and the used medium was aspirated 3 before adding 250 µl of the respective dilution to each well. Cells were incubated for 6 h at 4 37 °C. Supernatants were then transferred into a U-bottom plate, centrifuged for 3 min at 5 800 x g and carefully transferred into another U-bottom plate. Supernatants were directly 6 used for ELISA measurements according to the manufacturer's protocol (Chromogranin A 7 ELISA Kit, Dako, Glostrup, DK). Inhibitor experiments were performed in complete medium 8 for 24 h after ligand application and supernatants were processed as described. 9 10
Metabolic activity 11
Cells were seeded in quadruplicates at a density of 5,000 cells in 50 µl medium per well in In vivo imaging 28 8-week-old immunodeficient NMRI-Foxn1 nu /Foxn1 nu mice (Janvier Labs, Le Genest-Saint-1 Isle, France) were inoculated with BON and QGP-1 cells to generate xenografts for in vivo 2 experiments. Tumor cells grown as monolayers in culture plates were harvested, counted 3 and the pellet was resuspended in serum-free medium at 1 x 10 7 cells/100 µl. Cells were 4 mixed 1:1 with Matrigel HC (Corning, Corning, USA), subcutaneously injected into the 5 shoulder of anesthetized mice (100 µl, 5 x 10 6 cells) and grown for 2-3 weeks. For in vivo 6 receptor targeting, the near-infrared fluorescent ITCC-labeled probe was applied 7 intravenously into tumor bearing mice via a lateral tail vein (1 nmol in 100 µl 0.9 % NaCl per 8 animal). Images were acquired prior to and at the indicated time points after injection with a 9
Pearl near-infrared imaging system (Licor, Lincoln, USA). Animals were imaged under 10 isoflurane anesthesia with an excitation at 785 nm and an emission at 820 nm. Images were 11 analyzed with the Pearl Cam Software by defining regions of interest to obtain mean 12 fluorescence intensities. From these, the ratio of signal (tumor) to background (neck) was 13 calculated. For ex vivo imaging, mice were sacrificed at 6 h after injection and tumors and 14 organs were surgically excised. Animal care followed institutional guidelines and all 15 experiments were approved by local animal research authorities. In order to identify potential cell surface targets in NEN cells, a 998-compound chemical 3 library mainly consisting of peptide receptor ligands ( Supplementary Table 1 ) was applied in 4 a primary screening for cellular activity in the human pancreatic NEN cell line BON. Both a 5 label-free dynamic mass redistribution (DMR) assay as well as an intracellular calcium 6 mobilization assay were employed in 384-well format ( Fig. 1A-C) . A total of 89 hits were 7 detected (8.9 %), which were assayed again in BON cells in a 96-well format ( Fig. 1D -E). 30 8 primary hits, including structurally related compounds, were confirmed in 96-well format in 9 the DMR assay, and 19 hits in the calcium assay, with 11 compounds confirmed in both 10 assays ( Supplementary Table 2 ). Angiotensin II (ATII) appeared consistently as a strong 11 activator of intracellular signaling in BON cells. This was subsequently validated in 12 concentration-response experiments using these cells in three different functional assay 13 types: DMR, calcium and impedance. The quantitative analysis showed an EC 50 for ATII of 14 0.88 ± 0.28 nM, 4.9 ± 5.2 nM and 0.45 ± 0.03 nM in DMR, calcium and impedance 15 measurements, respectively ( Fig. 1F-H) . analyzed for their AGTR1 mRNA levels. Small-intestinal NEN (siNEN) demonstrated 1 significantly (p<0.001) increased AGTR1 transcript levels, with an overall 2.8-fold higher 2 median value in comparison to healthy control tissues, whereas pancreatic tissues showed 3 no significant difference (Fig. 2B ). Taking the median value of the siNEN samples as a cut-4 off, 50% of tumor samples yet only 7.7% of controls were above that value. When all NENs 5 were compared to all controls, differences were also significant (3.6-fold higher median, 6
p<0.01). The same samples were also analyzed for expression of the established NEN target 7 SSTR2, which was found to be significantly upregulated in both pancreatic and siNEN 8 tissues, as expected. The ratio of NEN to control median values, was higher for SSTR2 (8.5 9 versus 3.6 for AGTR1). However, AGTR1 was detected at an approximately 10-fold higher 10 expression level than SSTR2. Correlation analysis confirmed a significant positive correlation 11 between AGTR1 and SSTR2 expression for small-intestinal NENs (Pearson r=0.37, p<0.001, 12 r²=0.14), whereas no significant correlation was found for pancreatic samples (r=-0.09) or all 13
NENs taken together (r=0.12) ( Fig. 2C) . 14
15
To verify AGTR1 gene expression employing an alternative methodology, ten normal control 16 samples from pancreas and small intestine as well as eight pancreatic and nine small-17
intestinal NEN samples were selected for the determination of receptor binding sites by in 18 vitro receptor autoradiography (patient characteristics: Supplementary Table 3 ). To this end, 19 the natural receptor ligand ATII was radioactively labeled with iodine-125 ( 125 I-ATII) and 20 purified by high-performance liquid chromatography (HPLC) ( Supplementary Fig. 1) . 21
Consecutive cryosections of each tissue were incubated with the radioligand in the absence 22 or presence of an excess of non-labeled ATII. To distinguish between receptor subtypes, 23 additional tissue sections were incubated with radioligand and AGTR1-specific antagonist 24 valsartan or AGTR2-specific antagonist PD123319 ( Fig. 3A, Supplementary Fig. 3-4) . 25
Pancreatic NEN tissues showed a rather weak overall binding of 125 I-ATII. Nevertheless, in 26 tissues #4 (Fig. 3A) , #1, #6 and #8 ( Supplementary Fig. 3 ), it could be clearly displaced by 27 ATII and valsartan, but not by PD123319, indicating dominant AGTR1 expression. Small-28
intestinal NENs, on the other hand, demonstrated a strong binding in more than half of the 1 samples (#9 to #13) ( Fig. 3A, Supplementary Fig.3 ). This proved to be AGTR1-specific 2 binding as it could only be displaced by valsartan. PD123319 was unable to compete with 3 the radioligand. In addition, pancreatic and small-intestinal control tissues were included in 4 the analysis (Fig. 3A, Supplementary Fig. 4 ). Interestingly, a number of pancreatic samples 5 exhibited strong radioligand binding. In comparison to pancreatic NEN samples, signals in 6 normal pancreas were displaced solely by PD123319, indicating a specific expression of 7 AGTR2. Small-intestinal control samples showed no binding at all (#23, #25) or non-specific 8 binding (#24, #26, #27) ( Supplementary Fig. 4 ). 9
10 Digitized autoradiograms were quantified by calculating the ratios of total binding to non-11 specific binding in the presence of excess ATII, valsartan or PD123319 ( Fig. 3B-D) . The 12 higher a ratio, the higher the expression of the respective receptor subtype. Indeed, 13 valsartan-related ratios were increased up to 5-fold in NEN tissues, especially in small-14
intestinal NENs, when compared to their respective control tissues. This confirmed a specific 15 AGTR1 expression ( Fig. 3C ). To verify these findings using a different quantitative analysis, 16
tissues were wiped off the slides after radioligand incubation and measured by a gamma 17 counter. This alternative quantification yielded similar results ( Supplementary Fig. 2) , 18 although image analysis after digitization revealed higher overall ratios. Quantitative data 19 from autoradiography was also compared to the gene expression data for the corresponding 20 samples. As depicted in Fig. 3E , mRNA levels could be well correlated with binding levels for 21 most tissues (Pearson r=0.43, p≤0.01, r 2 =0.184). Whereas controls showed low mRNA and 22 low binding levels, NENs in general had relatively high mRNA and binding levels. A similar 23 correlation done with data from the alternative quantification confirmed this result 24 ( Supplementary Fig. 2B ). Furthermore, AGTR1 mRNA levels of the samples analyzed by 25 autoradiography were individually compared to those of SSTR2 mRNA (Fig. 3F ). All these 26 NEN tissues showed higher AGTR1 than SSTR2 mRNA levels. 27
28
After target validation in patient tissues, receptor-positive cell lines BON and H727 were 1 further evaluated as models for AGTR1 expression and function in NEN. Confirming previous 2 gene expression data ( Fig. 2A) , both cell lines exhibited significant specific binding of 125 I-3
ATII that could be displaced by unlabeled ATII, whereas the other NEN cell lines QGP-1, 4
LCC-18 and UMC-1 demonstrated only background levels of radioligand binding (Fig. 4A) . To gain an understanding of the biological function of AGTR1 in NEN cells, cellular signaling, 20 secretion and cell viability of BON and H727 cells were evaluated upon receptor stimulation 21 or inhibition. Functional activation of the receptor was studied by an intracellular calcium 22 mobilization assay. While concentration-dependent response curves could be obtained for 23 BON and H727, demonstrating functionally active receptor in these cells, QGP-1 and LCC-18 24 cells showed no calcium influx (Fig. 5A ). Furthermore, valsartan was able to significantly 25 diminish the induced signal, while PD123319 did not influence receptor activation, indicating 26 selective AGTR1, not AGTR2 signaling (Fig. 5A) . The AGTR1-selective antagonist valsartan 27 inhibited ATII-mediated calcium mobilization in a concentration-dependent manner (Fig. 5B) . 28
Gα q inhibition completely abolished the calcium signal, whereas β-arrestin blockage did not 1 modulate calcium mobilization in either BON or H727 cells. Inhibition of ERK or AKT also did 2 not change the calcium response in BON cells (Fig. 5B) . 3 4 As NENs often secrete chromogranin A (CgA), BON cell supernatants were tested for their 5
CgA content after ATII treatment. Interestingly, CgA secretion in these cells was stimulated in 6 a concentration-dependent manner. CgA secretion was diminished after preincubation with 7 AGTR1 antagonist valsartan (Fig. 5C ). When investigating metabolic activity as a readout for 8 cell growth and viability, no change could be detected in BON and H727 cells 96 hours after 9 treatment with different concentrations of agonist (ATII) or antagonist (valsartan) (Fig. 5D ). 10
11
Finally, the capacity of AGTR1 to act as a target for in vivo molecular diagnostic imaging was 12 assessed. To this end, the partial AGTR1/2 agonist saralasin was coupled via a 4,7,10-13 trioxatridecan-succinamic acid (TTDS) linker to the near-infrared fluorescent dye 14 indotricarbocyanine (ITCC). Radioligand binding assays with 125 I-ATII were conducted to 15 determine the affinity of the fluorescent probe in vitro (Fig. 6A) . In AGTR1-positive BON cells, 16
the radioligand could be displaced by unlabeled ATII confirming its high affinity (K i = 0.1 nM) 17 as determined before (Fig. 4C ). The binding curve of saralasin-ITCC was shifted to the right, 18 indicating lower binding affinity at a K i value of 246.5 nM. In contrast, receptor negative 19 QGP-1 cells did not show binding at all. For in vivo imaging, immunodeficient nude mice 20 were subcutaneously inoculated with BON cells on the right and QGP-1 cells on the left 21 shoulder. Near-infrared fluorescent imaging was performed after sufficient tumor growth and 22 the ITCC-labeled probe was tested in four different animals. Biodistribution kinetics of 23 saralasin-ITCC of one animal after intravenous application is shown in Fig. 6B . Visual 24 evaluation of the images indicated a selective accumulation of saralasin-ITCC in AGTR1-25 positive BON tumors, which proved to be statistically significant at three, four, five and six 26 hours post-injection after quantitative analysis (Fig. 6C) . Tumor-to-background ratios were 2-27 to 3-fold higher when compared to the image acquired prior to injection. In contrast, only low, 28 non-significant uptake was detected in receptor negative QGP-1 tumors. Ventral images of 1 the animals showed that the majority of the probe was excreted via the bladder. Ex vivo 2 organ imaging 6 hours after injection confirmed the specificity of saralasin-ITCC for receptor-3 positive BON tumors as well as an increased accumulation in kidneys and liver (Fig. 6D) . 4
Similarly, AGTR1 small molecule antagonist valsartan was labeled with ITCC via a 1,3-5 diamino propane linker and used for the same type of imaging. Although the affinity of this 6 fluorescent ligand conjugate (IC 50 =18.6 nM) was higher than for saralasin-ITCC, the 7 accumulation of valsartan-ITCC in AGTR1-positive NEN xenograft tumors proved to be less 8 pronounced ( Supplementary Fig. 5 ). 9
Discussion 1 ATII is the major effector of the renin-angiotensin system, regulating blood pressure and 2 cardiovascular homeostasis. Apart from this canonical role, ATII is involved in angiogenesis, 3 inflammation, cell proliferation, differentiation and tissue remodeling. Consequently, 4 activation of ATII and its cognate receptors may be relevant to carcinogenesis (19, 20) . So 5 far, the ATII receptor type 1 (AGTR1) was found to be overexpressed in various cancers, 6 such as breast (21), gastric (22) and pancreatic cancer (23,24). 7
In search of alternative targets that may be used for diagnosis and treatment of NENs, this 8 study employed cell-based screening in human NEN cells using a compound library of 998 9 peptides and small molecules. This approach yielded 38 confirmed hits, including ATII and a positive correlation between AGTR1 and SSTR2 expression in these samples, however, a 17 subset of patients with low SSTR2 and high AGTR1 expression could benefit from tumor 18 targeting approaches based on AGTR1 ligands. While mRNA expression data provide 19 important insights into differentially regulated transcript levels, the existence of sufficient 20 receptor protein at the cell surface is a prerequisite for molecular targeting. In a previous 21 study, AGTR1 protein expression in 44 pancreatic NENs had been evaluated by 22 immunohistochemistry (25). This paper observed an expression in 80 % of the patients. 23
However, the antibody employed in this paper was demonstrated to be non-specific in two 24 studies (26,27). In the current study, protein expression was indirectly evaluated by receptor 25 autoradiography as an alternative more reliable method than antibody-based techniques. To 26 discriminate between AGTR1 and AGTR2, subtype selective antagonists were co-applied for 27 radioligand displacement and assessment of nonspecific binding. Quantification revealed an 28 up to 5-fold higher binding of AGTR1 in pancreatic, and in particular in small-intestinal NENs. 1
This was found to correlate well with mRNA expression for most samples. To identify appropriate models for investigating the impact of ATII on tumor-associated 11 processes such as signaling, secretion and proliferation, a panel of 28 cell lines was tested 12 for AGTR1 expression. Indeed, the two cell lines with the highest AGTR1 mRNA expression, 13 BON and H727, were of NEN origin, whereas only one colon and one lung cancer cell line 14 reached similarly high values. This may indicate that AGTR1 overexpression is not a general 15 phenomenon in tumors, but may be of particular relevance to NENs. Specific AGTR1 16 expression in these cell lines was further confirmed by radioactive binding assays and 17 autoradiography before applying them for in vitro and in vivo experiments. 18 AGTR1 is known to primarily couple to the heterotrimeric G protein Gq/11 (20) . This study 19 confirmed for ATII-mediated mobilization of intracellular calcium in BON and H727 cells, 20 blocked by valsartan and Gq inhibitor UBO-QIC. As Calcium acts as a versatile second 21 messenger, physiological processes such as secretion and proliferation were investigated in 22 more detail. Enhanced calcium channel activity had been previously associated with an 23 increased release of the NEN marker chromogranin A (CgA) and of neurotensin (30,31). 24
Indeed, ATII concentration-dependently stimulated CgA secretion in BON cells. Physiological 25 or enhanced ATII levels in the circulation of NEN patients may therefore contribute to 26 hormone hypersecretion. Several studies showed that ATII facilitates cell proliferation in 27 various human cancer cell lines, including breast (32), prostate (33) and pancreatic cells 1 (34). The proposed pro-proliferative effect, however, could not be confirmed in this study, as 2 metabolic activity was not affected in BON and H727 cells. Likewise, treatment with the 3 AGTR1 antagonist valsartan revealed no inhibition of cell growth. One could hypothesize that 4 BON and H727 release ATII, which may lead to autocrine signaling and enhanced cell 5 proliferation making externally added treatment negligible. This would be in line with a 6
previous study in which treatment with the ACE inhibitor enalapril, and thereby inhibition of 7 ATII production, resulted in decreased BON cell growth in vitro and in vivo (25). Similarly, the 8 effect of applied antagonists might be impaired as they have to compete with autocrine ATII 9 binding for the receptors (35). It is also conceivable that a lack of one or more signaling 10 components prevents the transduction of the signal from the receptor to the cell cycle 11 machinery. Furthermore, ATII mediates its pro-proliferative signaling not only by direct 12 stimulation of tumor cells, but also indirectly affects stromal and vascular cells (20), which are 13 not present in most monolayer cell cultures. 14 Following target identification and validation, the suitability of AGTR1 as a target for optical in 15 vivo imaging was assessed. Radiolabeled AGTR1-targeted peptides and small molecules 16
have been primarily utilized for cardiac and cardiovascular imaging so far, to select patients 17 for distinct treatment options and to better predict therapy response (36). To the best of our 18 knowledge, this is the first study investigating the applicability of AGTR1-based tumor 19 targeting. For this, the partial receptor agonist saralasin, containing three amino acid 20 substitutions in comparison to ATII, as well as the small molecule AGTR1-antagonist 21 valsartan were chosen. Biodistribution of the two different ITCC-labeled targeted ligands was 22 evaluated in a xenograft mouse model. This revealed a significant accumulation of 23 saralasin-ITCC in receptor-positive BON tumors after a few hours. Valsartan-ITCC was taken 24 up to a lesser extent in both BON and receptor-negative QGP-1 ( Supplementary Figure 5) . 25
The superior performance of saralasin-ITCC was unexpected, as the introduction of the dye 26 molecule ITCC decreased its affinity 250-fold, compared to the published K i value of 1 nM 27 (37). Although a slow dissociation rate from the receptor is mostly associated with high 28 affinity binding, both parameters do not necessarily have to correlate (38). Furthermore, 1 saralasin exhibits a half-life of a few minutes whereas valsartan is stable for a few hours 2 (39,40). It is of notice though that saralasin-ITCC was quite rapidly eliminated via kidney and 3 bladder, while valsartan-ITCC remained much longer in the mouse and was mainly excreted 4 hepatically. 5
Although the tumor-to-background ratio for saralasin-ITCC was significantly increased in 6 receptor-positive BON tumors, several modifications might further enhance probe 7 performance. The introduction of a more hydrophobic linker between peptide and dye could 8 result in longer retention, and hence, higher uptake and overall fluorescence intensities. 9
Linker molecules such as aminohexanoic acid (AHX) are commonly used to increase the 10 hydrophobicity of a molecule, whereas trioxatridecansuccinamic acid (TTDS) or polyethylene 11 glycol (PEG) are more hydrophilic. In addition, the variation of linker length and thus the 12 distance between peptide and near-infrared dye, might enhance the affinity of the probe (44). 13
The proof of principle for AGTR1-based tumor imaging in this study may pave the way for a 14 translation into diagnostic approaches like PET imaging and AGTR1-directed peptide 15 receptor radioligand therapy (PRRT) for NENs employing chelator-based AGTR1 
